Teriparatide

Teriparatide is a recombinant peptide consisting of the first 34 amino acids of human parathyroid hormone (PTH), an 84-amino-acid hormone normally secreted by the parathyroid glands to regulate calcium homeostasis. This 34-residue N-terminal fragment retains the full biological activity of the intact hormone and is manufactured using a strain of Escherichia coli modified by recombinant DNA technology, making Teriparatide one of the larger and more structurally complex peptides profiled in this catalog.

At Verified Peptides, we think Teriparatide holds a genuinely distinctive place in osteoporosis treatment history: FDA-approved in 2002 (as Forteo, manufactured by Eli Lilly), it was the first anabolic (bone-forming) therapeutic agent available for osteoporosis, in contrast to the antiresorptive drug class (bisphosphonates, and later denosumab) that had previously dominated osteoporosis treatment by slowing bone breakdown rather than actively stimulating new bone formation.

Chemically, Teriparatide has molecular formula C181H291N55O51S2, molecular weight approximately 4117.77 g/mol, CAS number 52232-67-4, PubChem CID 16132393. Its considerably larger size relative to most peptides in this catalog (34 residues versus the 3-13 residue range typical of the cosmetic and GnRH-analog peptides profiled elsewhere) reflects its origin as a fragment of a much larger native protein hormone rather than a fully synthetic short-sequence design.

Because Teriparatide is manufactured via recombinant bacterial expression rather than solid-phase chemical synthesis (the method used for essentially every other peptide in this catalog), its production process more closely resembles that of larger biologic drugs like insulin or growth hormone than the shorter synthetic peptides profiled elsewhere on this site. This distinction is relevant to purity and identity testing, since recombinant production introduces different potential impurity profiles (such as host-cell protein residuals or truncated expression products) than chemical synthesis does.

At Verified Peptides, we think Teriparatide has one of the most rigorous and historically significant evidence bases in this entire catalog. The pivotal citation is Neer et al. (2001, New England Journal of Medicine, PMID 11346808, volume 344, issue 19, pages 1434-1441), a randomized, double-blind, placebo-controlled trial randomly assigning 1,637 postmenopausal women with prior vertebral fractures to receive 20 μg or 40 μg of PTH(1-34) or placebo, administered subcutaneously daily. The trial found a 65-67% reduction in new vertebral fractures and a 38% reduction in non-vertebral fractures, alongside increased bone mineral density at the lumbar spine and femoral neck — a large, rigorously controlled, clinically decisive trial that directly supported Teriparatide's 2002 FDA approval and its designation as the first anabolic osteoporosis therapy.

We also want to highlight a genuine, positive regulatory-science story specific to this compound: Teriparatide originally carried an FDA boxed warning regarding osteosarcoma (a rare bone cancer) observed in rat carcinogenicity studies at high, prolonged doses. Krege et al. (2022, JBMR Plus, PMID 36111201) documented the subsequent history of this warning, including two large postmarketing surveillance studies linking pharmacy claims data to state cancer registries, which found no increase in osteosarcoma incidence among Teriparatide-treated patients compared to unexposed populations or expected background rates. Based on this accumulated real-world evidence, the FDA formally removed the boxed warning in November 2020, retaining only a standard warnings/precautions-section note reflecting continued uncertainty for very-long-term use, and also relaxed the previous 24-month lifetime treatment duration limit. We think this is a genuinely useful case study in how postmarketing surveillance can meaningfully revise an initial safety signal derived from animal studies once real human outcomes data accumulates. We also want to note that Teriparatide's clinical evidence base extends well beyond the original Neer trial: separate randomized studies established its efficacy specifically in men with osteoporosis (PMID 12510800) and examined its effects on cortical bone specifically in postmenopausal women (PMID 12619939), broadening the population and bone-compartment-specific evidence beyond the pivotal vertebral-fracture trial. Later research also examined Teriparatide in combination with or compared against bisphosphonates such as alendronate, generally finding that combining an anabolic agent with an antiresorptive agent does not straightforwardly produce additive benefits and, in some regimens, can blunt the anabolic response — a somewhat counterintuitive finding that has shaped how these two drug classes are sequenced in clinical practice.

At Verified Peptides, we sell research-grade Teriparatide exclusively for laboratory research, and we think this compound's evidence base — spanning a landmark placebo-controlled efficacy trial and a rare, genuine safety-warning-removal history — represents one of the strongest and most transparently documented regulatory records in this catalog.

Parathyroid hormone's native physiological role centers on calcium homeostasis: continuous PTH secretion in response to low blood calcium mobilizes calcium from bone, increases renal calcium reabsorption, and activates vitamin D, all working to restore normal blood calcium levels — a catabolic, bone-mobilizing function at the organism level that stands in direct contrast to Teriparatide's therapeutic anabolic effect when administered in a deliberately different (intermittent, once-daily) pattern.

The 2001 Neer trial's fracture-reduction results (65-67% vertebral, 38% non-vertebral) remain among the largest relative risk reductions reported for any osteoporosis therapy class, a benchmark that subsequent osteoporosis drugs, including other anabolic agents like abaloparatide (a related PTH-receptor-related-protein analog) and antiresorptive/anabolic combination approaches like romosozumab, have been compared against in the decades since.

Teriparatide's original 24-month lifetime treatment duration limit reflected an abundance of regulatory caution based on the rat carcinogenicity signal at initial approval, rather than evidence of reduced efficacy or increased risk specifically at longer durations in humans — the 2020 label update relaxing this limit is a direct consequence of the accumulated postmarketing safety data discussed in the research summary above, illustrating how initial regulatory caution can be appropriately revised as more real-world evidence accumulates, without that caution having been inappropriate to apply at the time of original approval.

Teriparatide's success also helped establish an entire subsequent category of bone-anabolic drug development: abaloparatide, a related analog of parathyroid hormone-related protein (PTHrP) rather than PTH itself, was later developed and FDA-approved (as Tymlos) using a broadly similar intermittent-dosing anabolic strategy, and romosozumab, a monoclonal antibody with a distinct mechanism (sclerostin inhibition) that also produces net anabolic bone effects, represents a structurally unrelated but conceptually adjacent approach to the same clinical goal of actively building new bone rather than merely slowing its loss.

At Verified Peptides, we require independent third-party HPLC purity testing and mass spectrometry identity confirmation for every batch of research-grade Teriparatide we offer, with a Certificate of Analysis (COA) available for each lot. As a larger, 34-residue recombinant peptide, correct folding and complete, accurate sequence synthesis across all 34 positions is particularly important to confirm, since even single-residue errors in a peptide this size could meaningfully affect biological activity.

We source exclusively from manufacturers operating under Good Manufacturing Practice (GMP)-aligned quality systems, and every lot is independently verified rather than accepted solely on a supplier's internal documentation. Researchers should always request and review the specific COA for the lot they receive, confirming purity percentage and molecular identity before use in any experimental protocol, including confirmation of full-length, correctly folded 34-residue product rather than truncated or aggregated expression byproducts that can occur with recombinant peptide manufacturing.

Lyophilized Teriparatide is stable when stored at -20°C, protected from light and moisture. At Verified Peptides, we ship lyophilized peptide with appropriate cold-chain packaging to preserve stability in transit.

Once reconstituted, solution should be stored refrigerated at 2–8°C and used within the timeframe indicated on the product's documentation, avoiding repeated freeze-thaw cycles. As a larger recombinant peptide, Teriparatide may be more susceptible to aggregation or degradation upon improper handling than the smaller synthetic peptides elsewhere in this catalog, so researchers should follow lot-specific reconstitution and handling guidance carefully.